Apriso
NDC 54868-6150
Product Information
Apriso is a NDA-approved product labeled by Physicians Total Care, Inc.. This medication is used to treat a certain bowel disease (ulcerative colitis). It is supplied as a blue product. This product entry covers the primary NDC 54868-6150 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
BLACK (C48323 - BLACK)
G;M
Code Structure Chart
Product Details
What is NDC 54868-6150?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- MESALAMINE (UNII: 4Q81I59GXC)
- MESALAMINE (UNII: 4Q81I59GXC) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) (UNII: 74G4R6TH13)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- TRIETHYL CITRATE (UNII: 8Z96QXD6UM)
- ASPARTAME (UNII: Z0H242BBR1)
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
- POVIDONE (UNII: FZ989GH94E)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 825130 - mesalamine 0.375 GM 24HR Extended Release Oral Capsule
- RxCUI: 825130 - 24 HR mesalamine 375 MG Extended Release Oral Capsule
- RxCUI: 825130 - mesalamine 375 MG 24 HR Extended Release Oral Capsule
- RxCUI: 825130 - mesalazine 375 MG 24 HR Extended Release Oral Capsule
- RxCUI: 825134 - Apriso 0.375 GM 24HR Extended Release Oral Capsule
* Please review the full disclaimer at the bottom of this page.